Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-22-026560
Filing Date
2022-05-02
Accepted
2022-05-02 21:48:13
Documents
2
Period of Report
2022-04-28

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1553
2 POA DOCUMENT poa.txt EX-24 3871
  Complete submission text file 0001209191-22-026560.txt   6832
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address C/O CYTOKINETICS, INCORPORATED 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
Bhanji Muna (Reporting) CIK: 0001846905 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37766 | Film No.: 22884361